Dear colleagues, Dear friends,

Don Leigh

Chairman of International Scientific Committee

We are very pleased to welcome you to the 23rd International Conference on Preimplantation Genetics (PGDIS 2026) organized by Preimplantation Genetic Diagnosis International Society in Shanghai, China, April 24-27, 2026.

The conference will be held in The Shanghai Expo Center, Shanghai, which is the world’s largest city and a major global hub, with excellent international connectivity. It blends cutting-edge technology, modern architecture, and historic neighborhoods along the Huangpu River. The city is known for its dynamic business environment, rich cultural scene, and world-class dining and hospitality, making it an ideal setting for an international scientific meeting.

This will be the first time that China has hosted PGDIS and we are sure that all attendees will be amazed at how this region has expanded the use of both IVF and Preimplantation Genetic Testing (PGT), as well as exploring the science underlying embryo development and embryo selection. As with all previous PGDIS conferences, there is a theme that underlies the event and in 2026 it will be ‘Transforming the Frontiers of Preimplantation Genetic Testing’.

During the conference we will explore new technologies, genetic testing and analysis, quality assurance, laboratory management as related to PGT (biopsy, sample handling, analysis), non-invasive PGT (niPGT) as well as delving into the genetics of embryos and aspects of PGT applications. We are pleased to say that there will be both a host of renowned local and regional experts as well as many foreign international experts discussing these and other topics. Continuing from PGDIS 2025, key speakers will discuss the population consequences of recessive disorders- this is an important area on the application of PGT -M and highlights its utility in complementing government health initiatives around the world.

The clinical value of PGT -A will be critically discussed - an area of controversy but one where rapid expansion and

utilization necessitate a better understanding of its overall value in IVF practices. Technology never stops progressing

and developments in the integration of genotype and chromosomal anomaly detection further enhance its clinical value.

Recently, focus has shifted from traditional known pedigree application to identifying carrier couples in the population to

prevent even a first occurrence. Expanded carrier screening has shed further light on reproductive issues. As

technology advances, the opportunity to investigate the whole embryo genome is becoming a reality and with it, the

potential to identify both inherited and de novo mutations. With this expanded knowledge about an embryo, the

possibility of looking at multi gene interactions is revealed. This is a contentious area in PGT with robust debate around

its technical limitations, clinical applications and socio-ethical implications.

As technologies develop, their uptake into areas such as PGT, will keep raising challenges but will also improve the

knowledge of the underlying biology and offer better embryo selection processes leading to improved overall success in

IVF . With easier access than ever before, this is a must-attend event for clinicians, counselors, embryologists and

scientists- in fact for everyone that works in the field of IVF and PGT. For both the knowledge available and the city

itself, Shanghai will be a conference to remember.

To stay informed of key events, details of scientific program, timetables, registration and submission deadlines, please

consult PGDIS Conference website: www.pgdis2026.org

Looking forward to welcoming you in Shanghai, China.

Zi-Jiang Chen

Chairman of Organizing Committee & Conference Chairman

Anver Kuliev

Executive Director of PGDIS

© The copyright of this website belongs to Vega International Travel. Reactions on the contents of this website can be sent to Vega International Travel.